1. Home
  2. KEQU vs CHRS Comparison

KEQU vs CHRS Comparison

Compare KEQU & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KEQU
  • CHRS
  • Stock Information
  • Founded
  • KEQU 1906
  • CHRS 2010
  • Country
  • KEQU United States
  • CHRS United States
  • Employees
  • KEQU N/A
  • CHRS N/A
  • Industry
  • KEQU Medical Specialities
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • KEQU Industrials
  • CHRS Health Care
  • Exchange
  • KEQU Nasdaq
  • CHRS Nasdaq
  • Market Cap
  • KEQU 161.8M
  • CHRS 84.2M
  • IPO Year
  • KEQU N/A
  • CHRS 2014
  • Fundamental
  • Price
  • KEQU $58.86
  • CHRS $0.82
  • Analyst Decision
  • KEQU
  • CHRS Buy
  • Analyst Count
  • KEQU 0
  • CHRS 3
  • Target Price
  • KEQU N/A
  • CHRS $4.68
  • AVG Volume (30 Days)
  • KEQU 16.9K
  • CHRS 1.3M
  • Earning Date
  • KEQU 06-25-2025
  • CHRS 08-07-2025
  • Dividend Yield
  • KEQU N/A
  • CHRS N/A
  • EPS Growth
  • KEQU N/A
  • CHRS N/A
  • EPS
  • KEQU 3.83
  • CHRS N/A
  • Revenue
  • KEQU $240,472,000.00
  • CHRS $272,251,000.00
  • Revenue This Year
  • KEQU N/A
  • CHRS N/A
  • Revenue Next Year
  • KEQU N/A
  • CHRS $106.56
  • P/E Ratio
  • KEQU $15.37
  • CHRS $1.90
  • Revenue Growth
  • KEQU 18.02
  • CHRS 19.87
  • 52 Week Low
  • KEQU $30.33
  • CHRS $0.66
  • 52 Week High
  • KEQU $71.33
  • CHRS $2.43
  • Technical
  • Relative Strength Index (RSI)
  • KEQU 80.39
  • CHRS 53.65
  • Support Level
  • KEQU $36.05
  • CHRS $0.72
  • Resistance Level
  • KEQU $40.39
  • CHRS $0.77
  • Average True Range (ATR)
  • KEQU 2.53
  • CHRS 0.04
  • MACD
  • KEQU 2.16
  • CHRS 0.01
  • Stochastic Oscillator
  • KEQU 95.24
  • CHRS 91.74

About KEQU Kewaunee Scientific Corporation

Kewaunee Scientific Corp is a designer and manufacturer of technical furniture products for industries investing in spaces where discovery occurs, typically in laboratories. It serves in end-use markets that are all commercial, Life sciences, pharma, education, government and military research, etc. The company operates through two segments: The domestic segment designs manufactures and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, laminate casework, flexible systems, and Others; The International segment provides facility design, engineering, construction, and project management from the planning stage through the testing and commissioning of laboratories. It generates the majority of its revenue from the Domestic business segment.

About CHRS Coherus BioSciences Inc.

Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.

Share on Social Networks: